Sorrento Therapeutics/ US83587F2020 /
2023-02-22 10:00:00 PM | Chg. - | Volume | Bid1:59:50 AM | Ask1:59:58 AM | High | Low |
---|---|---|---|---|---|---|
0.3073USD | - | 176.99 mill. Turnover: 50.92 mill. |
0.2800Bid Size: 45,600 | 0.2842Ask Size: 200 | 0.4735 | 0.2580 |
GlobeNewswire
03-27
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Sh...
GlobeNewswire
03-15
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Defini...
GlobeNewswire
03-02
Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Ther...
GlobeNewswire
02-26
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sh...
GlobeNewswire
01-08
Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlight...
GlobeNewswire
2023-10-27
UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for th...
GlobeNewswire
2023-10-27
Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern...
GlobeNewswire
2023-10-08
Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potentia...
GlobeNewswire
2023-10-04
Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend ...
GlobeNewswire
2023-10-03
Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Sha...
GlobeNewswire
2023-09-21
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the...
GlobeNewswire
2023-09-13
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Com...
GlobeNewswire
2023-09-12
Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) ...
GlobeNewswire
2023-09-12
Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain We...
GlobeNewswire
2023-09-12
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate...
GlobeNewswire
2023-09-11
Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Prelimin...
GlobeNewswire
2023-09-07
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) f...
GlobeNewswire
2022-03-29
Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Couns...
GlobeNewswire
2022-03-23
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mount Raini...
GlobeNewswire
2022-03-20
Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Pote...
GlobeNewswire
2022-03-17
Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Public...
GlobeNewswire
2022-03-02
Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infectio...
GlobeNewswire
2022-03-02
Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIEL...
GlobeNewswire
2022-03-01
Invectys appoints Jian Cao, Ph.D., as Vice President, Pharmaceutical Development